An alkylating agent of value against both hematologic malignancies and solid tumors.
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A specific pair of GROUP F CHROMOSOMES of the human chromosome classification.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
An antineoplastic agent with alkylating properties. It also acts as a mutagen by damaging DNA and is used experimentally for that effect.
A filament-like structure consisting of a shaft which projects to the surface of the SKIN from a root which is softer than the shaft and lodges in the cavity of a HAIR FOLLICLE. It is found on most surfaces of the body.
Absence of hair from areas where it is normally present.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Natural recurring desire for food. Alterations may be induced by APPETITE DEPRESSANTS or APPETITE STIMULANTS.
Those persons legally qualified by education and training to engage in the practice of pharmacy.
A tube-like invagination of the EPIDERMIS from which the hair shaft develops and into which SEBACEOUS GLANDS open. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (Stedman, 26th ed) Follicles of very long hairs extend into the subcutaneous layer of tissue under the SKIN.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
A species of ENTEROVIRUS which is the causal agent of POLIOMYELITIS in humans. Three serotypes (strains) exist. Transmission is by the fecal-oral route, pharyngeal secretions, or mechanical vector (flies). Vaccines with both inactivated and live attenuated virus have proven effective in immunizing against the infection.
Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).
Certification as complying with a standard set by non-governmental organizations, applied for by institutions, programs, and facilities on a voluntary basis.
The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.
A private, voluntary, not-for-profit organization which establishes standards for the operation of health facilities and services, conducts surveys, and awards accreditation.
Information intended for potential users of medical and healthcare services. There is an emphasis on self-care and preventive approaches as well as information for community-wide dissemination and use.
Protective measures against unauthorized access to or interference with computer operating systems, telecommunications, or data structures, especially the modification, deletion, destruction, or release of data in computers. It includes methods of forestalling interference by computer viruses or so-called computer hackers aiming to compromise stored data.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Therapeutic approach tailoring therapy for genetically defined subgroups of patients.
Services offered to the library user. They include reference and circulation.
A solid tumor consisting of a dense infiltration of MAST CELLS. It is generally benign.
Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.
A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.
Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR.

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (1/257)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

L-Asparagine synthetase in serum as a marker for neoplasia. (2/257)

L-Asparagine synthetase appears in serum approximately 7 days after the s.c. implantation of 1 X 10(5) cells of Leukemia 5178Y/AR (resistant to L-asparaginase) and increases in activity as the neoplasm grows and metastasizes. The principal source of the enzyme is the primary tumor. After intravranial inoculation of tumor, the rate of leakage of the enzyme is more pronounced than when the subcutaneous, intramuscular, or intraperitoneal routes are used. 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037), a nitro-sourea effective in the palliation of L5178Y/AR, temporarily halts the influx of enzyme into the blood stream, as does surgical excision of the s.c. tumor nodules. Treatment of mice with L-asparaginase within 24 hr of inoculation of the tumor markedly augments both tumor growth and the rate of penetration of L-asparagine synthetase into the circulation. Several other L-asparagine synthetase into the circulation. Several other L-asparaginase-resistant tumors also were found to spill L-asparagine synthetase into the serum, but the correlation between this phenomenon and the specific activity of the enzyme in homogenates of the tumor was imperfect.  (+info)

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. (3/257)

Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy. High-dose therapy with autologous stem cell support has become the standard salvage therapy for patients failing chemotherapy, but there have been reports of a high incidence of myelodysplasia/acute myeloid leukaemia (MDS/AML) following such treatment. Patients who receive such therapy form a selected group, however, who have already been subjected to other leukaemogenic factors, such as treatment with alkylating agents. In order to ascertain the true risk of MDS/AML, comparison must be made with other patients subjected to the same risks but not undergoing transplantation. We report a retrospective comparative study of 4576 patients with Hodgkin's disease from the BNLI and UCLH Hodgkin's databases, which includes 595 patients who have received a transplant. Statistical analysis including Cox's proportional hazards multivariate regression model with time-dependent covariates was employed. This analysis reveals that the risk of developing MDS/AML was dominated by three factors, namely quantity of prior therapy (relative risk [RR] 2.01, 95% confidence intervals [CI] 1.49-2.71, for each treatment block, P < 0.0001) and whether the patient had been exposed to MOPP (RR 3.61, 95% CI 1.64-7.95, P = 0.0009) or lomustine chemotherapy (RR 4.53, 95% CI 1.96-10.44, P = 0.001). Following adjustment for these factors in the multivariate model the relative risk associated with transplantation was 1.83 (95% CI 0.66-5.11, P = 0.25). This study provides no evidence of a significantly increased risk of MDS/AML associated with BEAM therapy and autologous transplantation in Hodgkin's disease. Concern over MDS/AML should not mitigate against the timely use of this treatment modality.  (+info)

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. (4/257)

PURPOSE: To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy. MATERIALS AND METHODS: The Radiation Therapy Oncology Group (RTOG) database was reviewed for patients with newly diagnosed AA treated according to protocols that included either BCNU or PCV adjuvant chemotherapy. All patients were treated with radiation therapy. The outcome analysis included overall survival, taking into account patient age, extent of resection, Karnofsky performance status (KPS), and treatment group (BCNU v PCV). Stratified and nonstratified Cox proportional hazards models were used, as well as an analysis using matched cases between the groups. RESULTS: A total of 257 patients were treated with BCNU according to RTOG protocols 70-18, 83-02, and 90-06; 175 patients were treated with PCV according to RTOG protocol 94-04. All pretreatment characteristics except KPS were well balanced by treatment group; 61% of the BCNU group had a KPS of 90 to 100 compared with 73% of the PCV group (P =.0075). No statistically significant difference in survival was observed in any age group or by KPS or extent of surgery. The stratified analysis also showed no trends for improved survival by treatment group (P =. 40). The Cox model identified only age, KPS, and extent of surgery as important variables influencing survival, not treatment group. Matching cases between groups using age, KPS, and surgery resulted in 133 matched pairs. No difference in survival was observed (P =. 41). In a Cox model in which each matched pair is a strata, there was no difference between groups (P =.20). CONCLUSION: Using this retrospective analysis, there does not seem to be any survival benefit to PCV chemotherapy. Future phase III studies for patients with AA may need to consider whether BCNU or PCV is used in the control arm.  (+info)

Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. (5/257)

PURPOSE: Medulloblastoma is the most common malignant brain tumor of childhood. After treatment with surgery and radiation therapy, approximately 60% of children with medulloblastoma are alive and free of progressive disease 5 years after diagnosis, but many have significant neurocognitive sequelae. This study was undertaken to determine the feasibility and efficacy of treating children with nondisseminated medulloblastoma with reduced-dose craniospinal radiotherapy plus adjuvant chemotherapy. PATIENTS AND METHODS: Over a 3-year period, 65 children between 3 and 10 years of age with nondisseminated medulloblastoma were treated with postoperative, reduced-dose craniospinal radiation therapy (23.4 Gy) and 55.8 Gy of local radiation therapy. Adjuvant vincristine chemotherapy was administered during radiotherapy, and lomustine, vincristine, and cisplatin chemotherapy was administered during and after radiation. RESULTS: Progression-free survival was 86% +/- 4% at 3 years and 79% +/- 7% at 5 years. Sites of relapse for the 14 patients who developed progressive disease included the local tumor site alone in two patients, local tumor site and disseminated disease in nine, and nonprimary sites in three. Brainstem involvement did not adversely affect outcome. Therapy was relatively well tolerated; however, the dose of cisplatin had to be modified in more than 50% of patients before the completion of treatment. One child died of pneumonitis and sepsis during treatment. CONCLUSION: These overall survival rates compare favorably to those obtained in studies using full-dose radiation therapy alone or radiation therapy plus chemotherapy. The results suggest that reduced-dose craniospinal radiation therapy and adjuvant chemotherapy during and after radiation is a feasible approach for children with nondisseminated medulloblastoma.  (+info)

Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage. (6/257)

The role of the mismatch repair pathway in DNA replication is well defined but its involvement in processing DNA damage induced by chemical or physical agents is less clear. DNA repair and cell cycle control are tightly linked and it has been suggested that mismatch repair is necessary to activate the G(2)/M checkpoint in the presence of certain types of DNA damage. We investigated the proposed role for mismatch repair (MMR) in activation of the G(2)/M checkpoint following exposure to DNA-damaging agents. We compared the response of MMR-proficient HeLa and Raji cells with isogenic variants defective in either the hMutLalpha or hMutSalpha complex. Different agents were used: the cross-linker N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea (CCNU), gamma-radiation and the monofunctional methylating agent N-methyl-N-nitrosourea (MNU). MMR-defective cells are relatively sensitive to CCNU, while no differences in survival between repair-proficient and -deficient cells were observed after exposure to gamma-radiation. Analysis of cell cycle distribution indicates that G(2) arrest is induced at least as efficiently in MMR-defective cells after exposure to either CCNU or ionizing radiation. As expected, MNU does not induce G(2) accumulation in MMR-defective cells, which are known to be highly tolerant to killing by methylating agents, indicating that MNU-induced cell cycle alterations are strictly dependent on the cytotoxic processing of methylation damage by MMR. Conversely, activation of the G(2)/M checkpoint after DNA damage induced by CCNU and gamma-radiation does not depend on functional MMR. In addition, the absence of a simple correlation between the extent of G(2) arrest and cell killing by these agents suggests that G(2) arrest reflects the processing by MMR of both lethal and non-lethal DNA damage.  (+info)

Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. (7/257)

PURPOSE: To study response to chemotherapy and the outcome of children treated for a relapsed anaplastic large-cell lymphoma (ALCL) and to evaluate the role of bone marrow transplantation (BMT) in these patients. PATIENTS AND METHODS: Clinical data concerning the 41 relapses that occurred in 119 patients with ALCL enrolled in 3 consecutive studies since 1975 were analysed. First-line treatment consisted of intensive chemotherapy according to the COPAD protocol for the first series of 12 patients treated between 1975 and 1989 and to the SFOP (French Society of Pediatric Oncology) HM protocols for the 30 patients treated between 1989 and 1997. Twenty-eight patients were treated with CV(B)A (CCNU, vinblastine, ara-C with or without bleomycin), and the others with miscellaneous protocols for recurrent disease. Fifteen patients underwent autologous BMT and 1 allogeneic BMT while in CR2. RESULTS: Thirty-six of forty-one (88%) patients achieved CR2. With a median follow-up of 5 years, 12 patients died, 9 of their disease and 29 patients are alive in CR2 (20 patients), CR3 (5 patients), CR4 (2 patients), CR5 (1 patient) or CR6 (1 patient). Overall and disease-free survival are respectively 69% (53%-82%) and 44% (29%-61%) at three years. In univariate analysis, patients treated with ABMT while in CR2 did not appear to have a better outcome than the other. Remarkably, a long-lasting remission was obtained in 8 of 13 patients treated with weekly vinblastine for a relapse including 6 relapses occurring after ABMT. CONCLUSIONS: Relapsed ALCL are highly chemosensitive but over 40% of the patients experience several relapses. Prolonged conventional chemotherapy based on vinblastine might, in some cases, be as efficient as short intensive treatment with ABMT.  (+info)

Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea. (8/257)

The contributions of defective mismatch repair (MMR) and the p53-response to cell killing by N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea (CCNU) were evaluated. MMR defects were previously shown to be associated with CCNU sensitivity (G. Aquilina et al., Cancer Res., 58: 135-141, 1998). Unexpectedly, eight MMR-deficient variants of the A2780 human ovarian carcinoma cell line were 3-fold more resistant to CCNU than the MMR-proficient parental cells. The variants were members of a preexisting subpopulation of drug-resistant A2780 cells. In addition to deficient expression of the MMR protein hMLH1, an essential component of the hMutL alpha repair complex, the variants exhibited alterations in the expression of other genes that influence drug sensitivity. Although A2780 cells possess a wild-type p53 gene, all of the clones contained a heterozygous G to T tranversion at codon 172. This change resulted in a Val to Phe substitution and was associated with a constitutive production of high levels of p53, which was inactive as a transcriptional activator of bax and p21. The hMLH1/p53 defective variants displayed a less prominent cell cycle arrest and reduced apoptosis after CCNU treatment. In contrast, MMR-defective A2780 variants, which had a similar hMutL alpha defect but retained a wild-type p53, did exhibit the expected CCNU sensitivity. Expression of a dominant-negative p53val135 increased CCNU resistance of both MMR-proficient and MMR-deficient A2780 cells. Thus, defective MMR and p53 influence CCNU sensitivity in opposite directions. Their effects are independent, and sensitization by defective MMR does not require a functional p53 response.  (+info)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain. Lomustine is a nitrosurea that crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomustine. A multicentre phase I/II study was conducted to assess the maximum-tolerated dose (MTD), safety and efficacy of the combination of temozolomide and lomustine in melanoma metastatic to the brain. Increasing doses of temozolomide and lomustine were administered in phase 1 of the study to determine the MTD. Patients were treated at the MTD in phase II of the study to six cycles, disease progression or unacceptable toxicity. Twenty-six patients were enrolled in the study. In phase I of the study, the MTD was defined as temozolomide 150 mg m(-2) days 1-5 every 28 days and lomustine 60 mg m(-2) on day 5 every 56 days. Dose-limiting ...
Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug,[2] thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use, although it is also used to treat Hodgkin lymphoma as a second-line option.[3] Lomustine has a long time to nadir (the time when white blood cells reach their lowest number). Unlike carmustine, lomustine is administered orally. It is a monofunctional alkylating agent, alkylates both DNA and RNA, has the ability to cross-link DNA.[4] As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.[5] Lomustine is cell-cycle nonspecific. It has also been used in veterinary practice as a treatment for mast cell tumors in ...
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of bevacizumab given together with lomustine is most effective in treating patients with glioblastoma multiforme in first recurrence.. PURPOSE: The primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone. ...
Lomustine is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. Lomustine is used to treat brain tumors in people who have already received surgery or radiation. Lomustine is also used to treat Hodgkins disease. Lomustine is sometimes given with other cancer medicines...
This study will consist of 4 study periods of up to 50 months in total, consisting of:. Screening Period - A maximum screening duration of 4 weeks.. Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months.. End of Treatment Visit - A minimum of 4 weeks post last treatment for both arms.. Follow-Up Period - Up to 24 months.. A total of approximately 280 patients will be randomized in a 1:1 ratio to receive either eflornithine + lomustine or lomustine alone. ...
Lomustine (or CCNU)(Marketed under the name CeeNU in US) is an alkylating nitrosourea compound used in chemotherapy. It is in the same family as streptozotocin. This is a highly lipid soluble drug, and thus crosses the blood brain barrier. This property makes it ideal for treating brain tumors, and is its primary use. Lomustine has a long time to nadir (the time when white blood cells reach their lowest number). ...
Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors. It has previously demonstrated anti-tumor activity in a small cohort of patients with recurrent glioblastoma (rGB). We conducted a non-comparative randomized phase II clinical trial investigating axitinib monotherapy versus axitinib plus lomustine (LOM) in patients with rGB. Primary endpoint was 6 month progression-free survival (6mPFS). Patients who progressed on axitinib-monotherapy were allowed to cross-over. Between August 2011 and July 2015, 79 patients were randomized and initiated axitinib monotherapy (n = 50; AXI) or axitinib plus lomustine (n = 29; AXILOM). Median age was 55y [range 18-80], 50M/28F. Baseline characteristics were well balanced between study arms. Nineteen patients in the AXI-arm crossed-over at the time of progression. Treatment was generally well tolerated. AXILOM patients were at higher risk for grade 3/4 neutropenia ...
Lomustine has the special ability to penetrate the blood/brain barrier which means it can be used to treat cancers of the nervous system.The usual tumors against which Lomustine is most commonly used are: lymphoma, mast cell tumors, brain tumors, kidney tumors, lung tumors, and melanoma.
Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away. Check with your doctor right away if you have any of the following symptoms: fever, chills, dry cough, sore throat, confusion, shortness of breath, swelling of the feet or lower legs, unusual bleeding or bruising, or yellow eyes or skin. While you are being treated with lomustine, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctors approval. Lomustine may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine since there is a chance they could pass the polio virus on to you. Also, avoid persons who have recently taken oral polio vaccine. Do not get close to them, and ...
Lomustine is a medicine available in a number of countries worldwide. A list of US medications equivalent to Lomustine is available on the Drugs.com website.
RATIONALE: Drugs used in chemotherapy, such as methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine, use different ways to stop cancer c
Lomustine: Search drug information, interaction, images & medical diagnosis. The most comprehensive database of medicines available in China, Hong Kong, Ta...
Sigma-Aldrich offers abstracts and full-text articles by [J Gregory Cairncross, Meihua Wang, Robert B Jenkins, Edward G Shaw, Caterina Giannini, David G Brachman, Jan C Buckner, Karen L Fink, Luis Souhami, Normand J Laperriere, Jason T Huse, Minesh P Mehta, Walter J Curran].
Wear impervious gloves when handling this medicine. Take this medicine by mouth with a glass of water. Follow the directions on the prescription label. To provide the correct dose for you, there may be capsules of different sizes and colors to take as a single dose. Make sure you understand how to take your dose. This medicine is usually taken as a single dose once every 6 weeks. Take your medicine at regular intervals. Do not take it more often than directed. Do not stop taking except on your doctors advice ...
Nausea, vomiting, loss of appetite, diarrhea, and mouth/lip sores may occur. Nausea and vomiting usually last for less than 24 hours, though loss of appetite can last for several days. Nausea and vomiting can be quite severe. In some cases, your doctor may prescribe medication to prevent/treat nausea and vomiting. Changes in diet such as eating several small meals or limiting activity may help decrease some of these effects. If these effects persist or worsen, notify your doctor or pharmacist promptly. Temporary hair loss may occur. Normal hair growth should return after treatment has ended. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. (See also Warning section.) Tell your doctor immediately if any of these unlikely but serious side effects occur: confusion, swelling of lower legs/feet, vision changes. Tell your doctor ...
2-cyclohexyl-4-methyl-5-phenylmethoxypent-1-en-3-ol - chemical structural formula, chemical names, chemical properties, synthesis references
Synergistic microbicidal compositions are disclosed, comprising 4,5-dichloro-2-cyclohexyl-3-isothiazolone and one or more known microbicides for more effective, and broader control of microorganisms in various systems.
2,6-Piperidinedione, 3-(4-aminophenyl)-3-cyclohexyl-. CAS 115883-22-2. Molecular Formula:C17H22N2O2. Molecular Weight:C17H22N2O2.
3S,4S)-4-amino-5-cyclohexyl-3-hydroxypentanoicacid;ACHPA,(3S,4S)-4-Amino-5-cyclohexyl-3-hydroxy-pentanoicacid;105192-90-3;AC1NRAJQ;SCHEMBL7151431;ZINC2526313;AKOS015909015;AM001310;4-AMINO-5-CYCLOHEXYL-3-HYDROXY-PENTANOICACID;I14- ...
** Buy @ High Discounts Online Pharmacys Guaranteed Lowest Price ! Generic Lomustine (CCNU) 40 mg Capsules @ $ 3.82 | *** BUY DIRECT from LEGAL PHARMACIES / WHOcGMP certified & FDA approved Manufacturers in Australia, Canada, EU, India, Mauritius, NZ, Singapore, Turkey, UK & USA a complete range of Generic and Branded Drugs for Cancer, AIDS/HIV, Anticoagulants, Antiviral, Cholesterol, Diabetes, Chronic Kidney Disease CKD/Anemia, COPD, Hepatitis, Immunosuppressive and Osteoporosis treatment.
The nitrosoureas are alkylating agents that are highly lipid soluble and share similar pharmacological and clinical properties. Carmustine (BCNU), lomustine
OPINION STATEMENT: Anaplastic oligodendroglial tumors have gained increasing interest with the emerging role of molecular markers and systemic chemotherapy during the past years. The long-term results of two landmark trials, RTOG 9402 and EORTC 26961, have resulted in a reconsideration of the appropriate therapeutic approaches for patients with these tumors. Both trials indicate that patients whose tumors harbor a 1p/19q co-deletion benefit particularly from the addition of procarbazine/lomustine (CCNU)/vincristine (PCV) chemotherapy to radiation therapy (RT). The median survival of patients with co-deleted tumors treated within the RTOG trial with PCV before irradiation was 14.7 years compared with 7.3 years of patients who received RT alone. Median overall survival has not been reached in the RT plus PCV arm of the EORTC trial, but a similar difference can be anticipated after a follow-up of more than 12 years. In contrast, no such benefit was observed for patients with tumors lacking 1p/19q ...
Anaplastic oligodendroglial tumors are rare neoplasms with no standard approach to treatment. We sought to determine patterns of treatment delivered over time and identify clinical correlates of specific strategies using an international retrospective cohort of 1013 patients diagnosed from 19812007. Prior to 1990, most patients received radiotherapy (RT) alone as initial postoperative treatment. After 1990, approximately 50 of patients received both RT and chemotherapy (CT) sequentially and/or concurrently. Treatment with RT alone became significantly less common (67 in 19801984 vs 5 in 20052007, P | .0001). CT alone was more frequently administered in later years (0 in 19801984 vs 38 in 20052007; P | .0001), especially in patients with 1p19q codeleted tumors (57 of codeleted vs 4 with no deletion in 20052007; P | .0001). Temozolomide replaced the combination of procarbazine, lomustine, and vincristine (PCV) among patients who received CT alone or with RT (87 vs 2 in 20052007). In the most recent time
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
The incorporation of lomustine, a hydrophobic anticancer drug into PLGA nanoparticles by interfacial deposition method was optimized. Based on the optimal parameters, it ..
CAS NO:76512-92-0; Chemical name:1H-Imidazole-4-carboximidic acid, 5-amino-1-cyclohexyl-, methyl ester ; physical and chemical property of 76512-92-0, 1H-Imidazole-4-carboximidic acid, 5-amino-1-cyclohexyl-, methyl ester is provided by ChemNet.com
Is anyone familiar with this type of brain cancer called Anaplastic oligodendroglioma? I tried to research it and either found technical info or very
To determine whether loss of mismatch repair (MMR) confers sensitivity to N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea (CCNU), the sensitivity of MMR-defective (MMR-) variants was compared to that of their parental cells. Loss of MMR confers between 2- and 5-fold hypersensitivity to CCNU on HeLa, Raji, or Chinese hamster ovary cells. We also examined whether the sensitivity to CCNU is a general feature of MMR- human tumor cells. The majority expressed O6-methylguanine-DNA-methyltransferase (MGMT; Mex+ phenotype) that confers resistance to CCNU independent of their MMR status. The single Mex- MMR- SW48 cells were 4-fold more sensitive to CCNU than the Mex- MMR+ SW620 cells. CCNU sensitivity of the Mex+ cells was analyzed after treatment with the MGMT inhibitor O6-benzylguanine. The MMR- AN3CA, LS174T, LoVo, and DU145 cells were 1.4-4.3-fold more sensitive to CCNU than the MMR+ HeLaS3, HT29, and A2780 cells. Hypersensitivity to CCNU was not seen in the MMR- cell lines DLD1, HEC1A, and HCT116, ...
CeeNu (Lomustine, CCNU) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of brain tumors, lymphomas, melanoma, lung and colon cancer
This pivotal trial will compare the efficacy and safety of trabedersen and standard chemotherapy regimens (temozolomide, carmustine, or lomustine), in patients
Phenol, 4-cyclohexyl-, carbonate (2:1) | C25H34O5 | CID 71356229 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
Comprehensive supplier list for Formamide, N-(1-cyclohexyl-2,2,6,6-tetramethyl-4-piperidinyl)-,Formamide, N-(1-ethenyl-5-hexenyl)-
1-Cyclohexyl-3-(p-sulfamoylphenethyl)urea-d11 is a Stable Isotope of Glipizide with CAS Registry No: 1794979-66-0 and is used for research and analytical purpose.CLEARSYNTH delivers this compound worldwide under 100% Money Back Guarantee
The number of clinical, histopathologic, and molecular prognostic markers to estimate the outcome of patients with various types of gliomas, including low-grade gliomas, is steadily increasing (2, 32). In contrast, few studies have tried to distinguish markers that characterize the natural course of disease from markers that predict PFS and OS in response to specific therapeutic measures. The observation until first PD of surgically treated patients followed without adjuvant radiotherapy, or chemotherapy is the only way to determine whether a marker predicts outcome in the absence of adjuvant DNA-damaging treatment and is thus a prognostic marker independent of radiotherapy and chemotherapy. For instance, 1p/19q deletion is strongly predictive for prolonged PFS and OS in patients with anaplastic oligodendroglial tumors (WHO grade III) who are treated with radiotherapy or radiotherapy plus nitrosourea-based chemotherapy or temozolomide alone (14, 33, 34). Yet, 1p/19q deletion did not predict PFS ...
Purpose: Transforming growth factor-beta (TGF-β) signaling plays a key role in tumor progression, including malignant glioma. Small molecule inhibitors such as LY2157299 monohydrate (LY2157299) block TGF-β signaling and reduce tumor progression in preclinical models. To use LY2157299 in the treatment of malignancies, we investigated its properties in a First-in-Human Dose (FHD) study in cancer patients. Experimental Design: Sixty five patients (58 with glioma) with measurable and progressive malignancies were enrolled. Oral LY2157299 was given as a split dose morning and evening on an intermittent schedule of 14 days on and 14 days off (=28-day cycle). LY2157299 monotherapy was studied in dose escalation (Part A) first and then evaluated in combination with standard doses of lomustine (Part B). Safety was assessed using Common Terminology Criteria for Adverse Events version 3.0, echocardiography/Doppler imaging, serum troponin I and brain natriuretic peptide (BNP) levels. Anti-tumor activity ...
Find quality suppliers and manufacturers of 220119-17-5(Avermectin A1a,25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-a-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-,(5Z)-) for price inquiry. where to buy 220119-17-5(Avermectin A1a,25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-a-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-,(5Z)-).Also offer free database of 220119-17-5(Avermectin A1a,25-cyclohexyl-4-O-de(2,6-dideoxy-3-O-methyl-a-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-,(5Z)-) including MSDS sheet(poisoning, toxicity, hazards and safety),chemical properties,Formula, density and structure, solution etc.
1-Cyclohexyl-1-butanol 4352-42-5 MSDS report, 1-Cyclohexyl-1-butanol MSDS safety technical specifications search, 1-Cyclohexyl-1-butanol safety information specifications ect.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URACs accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch ...
Clinical trial for Brain and Central Nervous System Tumors , Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
When used to treat Hodgkins Lymphoma, it is often delivered as part of the MOPP regimen that includes Mechlorethamine, Vincristine (tradename Oncovin), Prednisone, and Procarbazine. Alternatively, when used to treat certain brain tumors (malignant gliomas), it is often dosed as PCV when combined with Lomustine (often called CCNU) and Vincristine.. Procarbazine is also part of the more modern BEACOPP regimen used for Hodgkins lymphoma.. ...
DNA is considered to be an important target for the antitumor and toxic properties of the chloroethylnitrosoureas. Since the main target for their dose-limiting toxicity and the antileukemic efficacy is believed to be the bone marrow, we have compared the formation and subsequent removal of DNA-DNA interstrand cross-links in the bone marrow of rats which had received a single i.p. injection (100 µmol/kg) of four chloroethylnitrosoureas. The kinetics of cross-link removal was identical for chlorozotocin, which is known to have low chemical carbamoylating activity, to that of 1,3-bis(2-chloroethyl)-1-nitrosourea, a drug with a relatively high carbamoylating capacity. The differential bone marrow toxicity exhibited by these two agents could not, therefore, be explained by a carbamoylation-mediated difference in the rate and extent of DNA-DNA interstrand cross-link removal. The peak level and overall magnitude of cross-links were, however, found to vary considerably with the chemical structure of ...
Alfa Chemistry is the worlds leading provider for special chemicals. We offer qualified products for 824949-98-6(1-CYCLOHEXYL-2-(3-FURANYL)-1H-BENZIMIDAZOLE-5-CARBOXYLIC ACID, METHYL ESTER),please inquire us for 824949-98-6(1-CYCLOHEXYL-2-(3-FURANYL)-1H-BENZIMIDAZOLE-5-CARBOXYLIC ACID, METHYL ESTER).
On One Hand: Drinking in Moderation is FineAccording to BreastCancer.org, you can probably drink moderate amounts of alcohol--one or two drinks at most per day--without doing any damage while on chemotherapy. Alcohol can actually help improve your appetite during chemotherapy.On the Other: It Depends on the DrugYou may have to give up drinking alcohol because it may prevent your chemotherapy drugs from working properly, according to CancerHelp UK. Procarbazine and lomustine are two common chemotherapy drugs that cause doctors to tell their patients not to drink.Bottom LineUsually, you can drink in moderation while undergoing chemotherapy a...
2-cyclohexyl-1-(1-dimethylamino-1H-pyrrol-2-yl)-propan-1-one - chemical structural formula, chemical names, chemical properties, synthesis references
66345-08-2 - LSDVOYHPXBALRS-UHFFFAOYSA-N - Phenol, 4-cyclohexyl-2-(1,1-dimethylethyl)-6-methyl- - Similar structures search, synonyms, formulas, resource links, and other chemical information.
The patient went on to have a resection. Histology Microscopic Description: Sections show brain tissue infiltrated by a glial tumour that displays oligodendroglial features. Tumour infiltration into adjacent brain tissue is represented by sub...
Procarbazine is used in the treatment of hodgkins disease.get complete information about procarbazine including usage, side effects, drug interaction, expert advice along with medicines associated with procarbazine at 1mg.com
A brain tumor is an abnormal mass of tissue in which cells grow and multiply seemingly unchecked by the mechanisms that control normal cells. The two main brain tumor groups are primary and metastatic.
Berardi F, Abate C, Ferorelli S, Uricchio V, Colabufo NA, Niso M, Perrone R (2009). „Exploring the importance of piperazine N-atoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28). Journal of Medicinal Chemistry. 52 (23): 7817-28. PMID 19842660. doi:10.1021/jm9007505 ...
We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy. 354 samples (79.2%) from the first operation of the 447 randomised patients provided enough tumour DNA for some or all parts of the study. Genome-wide array comparative genomic hybridisation (aCGH), mutation analysis of IDH1/2 and TP53 and methylation analyses of the MGMT CpG-island was done. 84% of grade III tumours and 17% of grade IV had IDH1 or IDH2 mutations that conferred a better prognosis in both; MGMT methylation (defined as average value across 16 CpGs ≥ 10%) occurred in 75% of tumours
Agarwal, Shweta and Jangir, Deepak Kumar and Singh, Parul and Mehrotra, Ranjana (2014) Spectroscopic analysis of the interaction of lomustine with calf thymus DNA. Journal of Photochemistry and Photobiology B: Biology, 130. pp. 281-286. ISSN 1011-1344 Agarwal , Shweta and Kumar Jangir, Deepak and Mehrotra, Ranjana and Lohani, Neelam and Rajeswari, M. R. (2014) A Structural Insight into Major Groove Directed Binding of Nitrosourea Derivative Nimustine with DNA: A Spectroscopic Study. PLoS ONE , 9 (8). pp. 104115-1. ISSN 1932-6203 Anurag , Jyoti and Pandey, Pratibha and Singh, Surinder Pal and Jain, Swatantra Kumar and Shanker, Rishi (2010) Colorimetric Detection of Nucleic Acid Signature of Shiga Toxin Producing Escherichia coli Using Gold Nanoparticles. Journal of Nanoscience and Nanotechnology, 10 (7). pp. 4154-4158. ISSN 1533-4880 ...
Gleostine® (lomustine) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to bleeding and overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of Gleostine® (see WARNINGS and ADVERSE REACTIONS).. Since the major toxicity is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose (see ADVERSE REACTIONS). At the recommended dosage, courses of Gleostine® should not be given more frequently than every 6 weeks.. The bone marrow toxicity of Gleostine® is cumulative and therefore dosage adjustment must be considered on the basis of nadir blood counts from prior dose (see dosage adjustment table under DOSAGE AND ADMINISTRATION). more ,, ...
Hi - I am new to this site and ama hoping to find some help here. My fiance had a seizure in June, which led to us finding out that he had this brain tumor. It was removed two days later and he just finished the 6 week radiation treatment along with the Chemo (oral Temador) at the same time. He is now 1 1/2 weeks into his one month off before starting the 5/28 day regiment. He has also been on Dilantin for the seizures since he first went in to the hospital afte having the first seizure. He decided that he did not need the medicine (or so he thought) any longer and had stopped taking the Dilantin for 4 days which then caused another seizure. After realizing the importance of staying on this medication and getting back on it now it seems that he is very nausauted and exremely tired now. He was not while having the radiation treatments or taking the Temador. Are the side effect worsened during the month off of treaments? Just looking to find answers as to why he is feeling so down now..... Any ...
Resection of ependymoblastoma (costs for program #217727) ✔ University Hospital Marburg UKGM ✔ Department of Neurosurgery ✔ BookingHealth.com
Diagnostics of ependymoblastoma (costs for program #205757) ✔ University Hospital Bonn ✔ Department of Oncology, Hematology, Rheumatology and Immunoncology ✔ BookingHealth.com
CHOP chemotherapy (cyclophosphamide, doxorubicin and vincristine chemotherapy with the steroid prednisolone) is the standard treatment for T-cell lymphoma. However, some people do not respond well to CHOP and alternative treatments are needed.
GDC-0425, also known as RG7602. is an oral, selective Chk1 inhibitor. GDC-0425 enhances gemcitabine (gem) efficacy in tumor xenograft models. Greater chemopotentiation is observed in cancer cell lines lacking p53 activity. GDC-0425 blocks the function of a protein called checkpoint kinase 1 (Chk1). GDC-0425 was safe and yielded responses in patients with a variety of cancer types, including triple-negative breast cancer, melanoma, and cancer of unknown primary, according to data from a phase I clinical trial presented at the AACR Annual Meeting 2015, held April 18-22.
When using this server please cite the following paper:. Zsila F, Bikadi Z, Malik D, Hari P, Pechan I, Berces A, Hazai E.. Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking.. Bioinformatics. 2011 May 18. ...
8-(1-hydroxyethyl)-1,3-dimethyl-7H-purine-2,6-dione,8-cyclohexyl-1,3-dimethyl-7H-purine-2,6-dione,8-(cyclohexylamino)-1,3-dimethyl-7H-purine-2,6-dione,8-[(4-aminophenyl)methyl]-1,3-dimethyl-7H-purine-2,6-dione,8-cyclohexyl-1,3,7-trimethyl-purine-2,6-dione,8-cyclohexyloxy-1,3,7-trimethyl-purine-2,6-dione,8-hexyl-1,3,7-trimethyl-purine-2,6-dione,8-[1,3-dimethyl-2,6-bis(oxidanylidene)-7H-purin-8-yl]octanoic acid,8-[1-[1,3-dimethyl-2,6-bis(oxidanylidene)-7H-purin-8-yl]ethyl]-1,3-dimethyl-7H-purine-2,6-dione,8-[3-[1,3-dimethyl-2,6-bis(oxidanylidene)-7H-purin-8-yl]propyl]-1,3-dimethyl-7H-purine-2,6-dione,8-[4-[1,3-dimethyl-2,6-bis(oxidanylidene)-7H-purin-8-yl]butyl]-1,3-dimethyl-7H-purine-2,6-dione,8-[5-[1,3-dimethyl-2,6-bis(oxidanylidene)-7H-purin-8-yl]pentyl]-1,3-dimethyl-7H-purine-2,6-dione,8-[6-[1,3-dimethyl-2,6-bis(oxidanylidene)-7H-purin-8-yl]hexyl]-1,3-dimethyl-7H-purine-2,6-dione,8-(diphenylmethyl)-1,3,7-trimethyl-purine-2,6-dione,8-[8-[1,3-dimethyl-2,6-bis(oxidanylidene)-7H-purin-8-yl]octyl]-1,3
Kann, H E.; Kohn, K W.; Widerlite, L; and Gullion, D, Effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds on nuclear rna metabolism. (1974). Subject Strain Bibliography 1974. 1674 ...
Hi, Julia.. We had a similar issue. David did not have the gene deletions (1p, 19q) that would make Temodar more effective. Different mutation since we are battling anaplastic oligodendroglioma, not AA3, but still the same difficult choice. We did Temodar anyway. I also was devastated when Davids FISH evaluation came back without the deletions. Our doctor at OHSU strongly recommended taking Temodar, but another doctor thought we should just do radiation and save Temodar for later. Our doctor strongly disagreed and told us that Temodar and radiation would have a synergistic effect if taken together. So thats what David did---he took Temodar while he did radiation, and then he continued to take it until April of this year.. I am glad that we did Temodar. I believe that it was the right choice for us. We knew going in that the doctors expected it to only be effective for a short time. But they told us that about every chemo. David had two years and 5 months with no tumor progression---no tumor at ...
Enhanced Misonidazole Binding in the Presence of AF-2 的翻译是: 是什么意思?英文翻译中文,中文翻译英文,怎么说?-我要翻译网
* Gileads once-daily quad pill to be sold as Stribild * Gilead to conduct further studies on safety, drug interactions * Shares unchanged after hours (Adds analyst comment, label information,
Redirects to Lomustine. CDDP CEA-Scan CEA-Cide cebaracetam (INN) Cebid Ceclor Cecon Cedax cedefingol (INN) cedelizumab (INN) ...
Tucci E, Verdiani P, Di Carlo S, Sforza V (1986). "Lomustine (CCNU)-induced pulmonary fibrosis". Tumori. 72 (1): 95-8. doi: ... Arabinopyranosyl-N-methyl-N-nitrosourea Carmustine Chlorozotocin Ethylnitrosourea Fotemustine Lomustine N-Nitroso-N-methylurea ... Fotemustine Lomustine (CCNU) Nimustine N-Nitroso-N-methylurea (NMU) Ranimustine (MCNU) Semustine Streptozocin (Streptozotocin) ... Nimustine Ranimustine Semustine Streptozocin Some nitrosoureas (e.g. lomustine) have been associated with the development of ...
5-Year relative survival rate: Age 20-44, 76%. Age 45-54, 67%. Age 55-64, 45%. Procarbazine, lomustine and vincristine have ...
A few different chemotherapeutic regimens for medulloblastoma are used; most involve a combination of lomustine, cisplatin, ...
These include: Bleomycin, chlorambucil, cyclophosphamide, cytarabine, doxorubicin, lomustine, mitoxantrone, topotecan, and ...
At therapeutic doses, those side effects are usually relatively milder compared with carmustine and lomustine. Pokrovskiĭ VS, ...
Treatment with chemotherapy has been used with some success, particularly using lomustine, prednisone, doxorubicin, and ...
It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off ...
Only small lipophilic alkylating agents such as lomustine or temozolomide are able to cross this blood-brain barrier. Blood ... Nitrosoureas include N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and ...
Bendamustine Lomustine Semustine CID 2578 from PubChem "Carmustine 100mg Powder and solvent for Solution for Infusion - Summary ...
Other chemotherapy drugs such as chlorambucil, lomustine (CCNU), cytosine arabinoside, and mitoxantrone are sometimes used in ...
Lomustine) (1976) BCNU (Carmustine) (1977) Cis-diamminedichloroplatinum (Cisplatin) (1978) Mitoxantrone (Novantrone) (1988) ...
... lomustine (INN) lonafarnib (USAN) lonapalene (INN) lonaprisan (USAN) lonaprofen (INN) lonazolac (INN) lonidamine (INN) Loniten ...
... lomustine - lonafarnib - loop electrosurgical excision procedure - loop excision - loperamide hydrochloride - losoxantrone - ...
... lomustine, dacarbazine developed by Y Fulmer Shealy, fludarabine, amifostine, clofarabine and the latest pralatrexate (approved ...
Lomustine, chlorambucil), neurotransmitters (dopamine, GABA), nerve growth factor (NGF) inducers, anticonvulsants (Phenytoin, ...
... has a long time to nadir (the time when white blood cells reach their lowest number). Unlike carmustine, lomustine is ... CeeNu (lomustine) Capsules data sheet published by the FDA Lomustine at the US National Library of Medicine Medical Subject ... Lomustine (CCNU; CeeNU)" (PDF). Retrieved 15 July 2016. "PRODUCT INFORMATION CeeNU®(lomustine)" (PDF). TGA eBusiness Services. ... Lomustine is cell-cycle nonspecific. It has also been used in veterinary practice as a treatment for mast cell tumors in dogs. ...
InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41?,42-,43-,53+,54-/m0/s1 ...
... is a drug used in chemotherapy. It is a semi-synthetic camptothecin analogue indicated for Small Cell Lung Cancer and Ovarian Cancer, approved in South Korea under the trade name Camtobell(R), presented in 2 mg vials for injection.[1] The drug is marketed by ChongKunDang Pharmaceuticals [2] since 2003 [3] Belotecan blocks topoisomerase I with a pIC50 of 6.56,[4] stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Topoisomerase I is an enzyme that mediates reversible single-strand breaks in DNA during DNA replication. ...
Nitrogen mustards arose from the derivatization of sulphur mustard gas after military personnel exposed to it during World War I were observed to have decreased white blood cell counts.[15] Since the sulphur mustard gas was too toxic to be used in humans, Gilman hypothesized that by reducing the electrophilicity of the agent, which made it highly chemically reactive towards electron-rich groups, then less toxic drugs could be obtained. To this end, he made analogues that were less electrophilic by exchanging the sulphur with a nitrogen, leading to the nitrogen mustards.[16] With an acceptable therapeutic index in humans, nitrogen mustards were first introduced in the clinic in 1946.[17] Aliphatic mustards were developed first, such as mechlorethamine hydrochloride (mustine hydrochloride) which is still used in the clinic today. In the 1950s, aromatic mustards like chlorambucil were introduced as less toxic alkylating agents than the aliphatic nitrogen mustards, proving to be less electrophilic ...
There are several ways molecules (in this case, also known as ligands) can interact with DNA. Ligands may interact with DNA by covalently binding, electrostatically binding, or intercalating.[1] Intercalation occurs when ligands of an appropriate size and chemical nature fit themselves in between base pairs of DNA. These ligands are mostly polycyclic, aromatic, and planar, and therefore often make good nucleic acid stains. Intensively studied DNA intercalators include berberine, ethidium bromide, proflavine, daunomycin, doxorubicin, and thalidomide. DNA intercalators are used in chemotherapeutic treatment to inhibit DNA replication in rapidly growing cancer cells. Examples include doxorubicin (adriamycin) and daunorubicin (both of which are used in treatment of Hodgkin's lymphoma), and dactinomycin (used in Wilm's tumour, Ewing's Sarcoma, rhabdomyosarcoma). Metallointercalators are complexes of a metal cation with polycyclic aromatic ligands. The most commonly used metal ion is ruthenium(II), ...
... (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in Japan since 2002 by Sumitomo under the brand name Calsed.[2] Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.[3][4] It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6] Amrubicin was the first anthracycline derivative created by de novo synthesis and was first published in 1989 by scientists from Sumitomo.[7] ...
In the late nineteenth century. Finsen successfully demonstrated phototherapy by employing heat-filtered light from a carbon-arc lamp (the "Finsen lamp") in the treatment of a tubercular condition of the skin known as lupus vulgaris, for which he won the 1903 Nobel Prize in Physiology or Medicine.[5] In 1913 another German scientist, Meyer-Betz, described the major stumbling block of photodynamic therapy. After injecting himself with haematoporphyrin (Hp, a photosensitiser), he swiftly experienced a general skin sensitivity upon exposure to sunlight-a recurrent problem with many photosensitisers.[5] The first evidence that agents, photosensitive synthetic dyes, in combination with a light source and oxygen could have potential therapeutic effect was made at the turn of the 20th century in the laboratory of Hermann von Tappeiner in Munich, Germany. Germany was leading the world in industrial dye synthesis at the time.[5] While studying the effects of acridine on paramecia cultures, Oscar Raab, a ...
During the 1950s and 1960s, the National Cancer Institute carried out a wide-ranging program of screening plant and marine organism material. As part of that program extract from the sea squirt Ecteinascidia turbinata was found to have anticancer activity in 1969.[1] Separation and characterisation of the active molecules had to wait many years for the development of sufficiently sensitive techniques, and the structure of one of them, Ecteinascidin 743, was determined by KL Rinehart at the University of Illinois in 1984.[2] Rinehart had collected his sea squirts by scuba diving in the reefs of the West Indies.[3] Recently, the biosynthetic pathway responsible for producing the drug has been determined to come from Candidatus Endoecteinascidia frumentensis, a microbial symbiont of the tunicate.[4] The Spanish company PharmaMar licensed the compound from the University of Illinois before 1994[citation needed] and attempted to farm the sea squirt with limited success.[3] Yields from the sea squirt ...
... was first made in 1963 by Ozegowski and Krebs in East Germany (the former German Democratic Republic).[9] Until 1990 it was available only in East Germany. East German investigators found that it was useful for treating chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and lung cancer. Bendamustine received its first marketing approval in Germany, where it is marketed under the tradename Ribomustin, by Astellas Pharma GmbH's licensee, Mundipharma International Corporation Limited. It is indicated as a single-agent or in combination with other anti-cancer agents for indolent non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. SymBio Pharmaceuticals Ltd. holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asia Pacific Rim countries. In March 2008, Cephalon received approval from the United States Food and Drug Administration to market bendamustine in the US, where it is sold under the ...
Research on this class of drugs began in the 1950s at SRI International, where scientists were focused on developing new chemotherapies and antifolates that would be effective against tumor cells.[1] In the late 1970s, researchers at Memorial Sloan Kettering Cancer Center discovered that cancerous cells take in natural folate through a protein identified as plasma membrane transporter (now referred to as "reduced folate carrier type 1" or "RFC-1"). Further research showed that when normal cells evolve into cancerous cells they often overproduce RFC-1 to ensure they get enough folate.[6] A subsequent scientific collaboration was ultimately formed among SRI International, Memorial Sloan Kettering Cancer Center, and the Southern Research Institute with the intention of developing an antifolate with greater therapeutic selectivity - an agent that could be more effectively internalized into tumors (transported into the cells through RFC-1) and would be more toxic to cancer cells than normal cells.[6] ...
Another amino acid-like drug is the antineoplastic agent melphalan. Tumor cells spend less time in resting phases than normal cells so at any given time, they are more likely to be metabolically active than most normal host cells. The rationale behind incorporating an alkylating function in a molecule resembling a primary cellular metabolite was to get a greater safety margin by fooling tumor cells into taking up the toxin preferentially. ...
... acts as an inhibitor of poly ADP ribose polymerase (PARP) which aids in single strand DNA repair. Cells that have BRCA1/2 mutations are susceptible to the cytotoxic effects of PARP inhibitors because of an accumulation of DNA damage.[2] Talazoparib is theorized to have a higher potency than olaparib due to the additional mechanism of action called PARP trapping. PARP trapping is the mechanism of action where the PARP molecule is trapped on the DNA, which interferes with the cells ability to replicate. Talazoparib is found to be ~100 fold more efficient in PARP trapping than olaparib.[9] However, this increased potency may not translate directly to clinical effectiveness as many other factors must be considered.[4][9] ...
Crosslinked DNA is repaired in cells by a combination of enzymes and other factors from the nucleotide excision repair (NER) pathway, homologous recombination, and the base excision repair (BER) pathway. To repair interstrand crosslinks in eukaryotes, a 3' flap endonuclease from the NER, XPF-ERCC1, is recruited to the crosslinked DNA, where it assists in 'unhooking' the DNA by cleaving the 3' strand at the crosslink site. The 5' strand is then cleaved, either by XPF-ERCC1 or another endonuclease, forming a double-strand break (DSB), which can then be repaired by the homologous recombination pathway.[17] DNA crosslinks generally cause loss of overlapping sequence information from the two strands of DNA. Therefore, accurate repair of the damage depends on retrieving the lost information from an undamaged homologous chromosome in the same cell. Retrieval can occur by pairing with a sister chromosome produced during a preceding round of replication. In a diploid cell retrieval may also occur by ...
Lomustine (CCNU; CeeNU)" (PDF). Retrieved 15 July 2016.. *^ "PRODUCT INFORMATION CeeNU®(lomustine)" (PDF). TGA eBusiness ... CeeNu (lomustine) Capsules data sheet published by the FDA. *Lomustine at the US National Library of Medicine Medical Subject ... Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an ... Unlike carmustine, lomustine is administered orally. It is a monofunctional alkylating agent, alkylates both DNA and RNA, has ...
Lomustine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking lomustine,. *tell your doctor and pharmacist if you are allergic to lomustine, any other medications, or any of ... Taking too much lomustine or taking it too often can cause serious, life-threatening problems. Take only one dose of lomustine ... Lomustine may increase the risk that you will develop other cancers. Talk to your doctor about the risks of taking lomustine. ...
Lomustine , Monograph containing literature references, physical and biological properties and relevant information ...
A list of US medications equivalent to Lomustine is available on the Drugs.com website. ... Lomustine is a medicine available in a number of countries worldwide. ... Lomustine. In the US, Lomustine (lomustine systemic) is a member of the drug class alkylating agents and is used to treat ...
This page contains brief information about lomustine and a collection of links to more information about the use of this drug, ... Lomustine is approved to be used alone or with other drugs to treat:. * Brain tumors. It is used in patients who have already ... More About Lomustine. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. ... MedlinePlus Information on Lomustine - A lay language summary of important information about this drug that may include the ...
Generic name Lomustine Pronunciation loh-MUS-teen Brand name(s), other common name(s) CeeNU®, CCNU Drug type DNA-damaging agent ... Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who ... Patients Disease Information Treatment Types of Treatment Chemotherapy and Other Drug Therapies Drug Listings Lomustine ...
Lomustine belongs to a class of drugs known as alkylating agents. It works by slowing or stopping the growth of cancer cells. ... Before taking lomustine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This ... During pregnancy, lomustine should be used only when clearly needed. It may harm an unborn baby. If you become pregnant or ... Lomustine may cause serious blood disorders (decreased bone marrow function leading to low number of white blood cells/ ...
Professional guide for Lomustine. Includes: pharmacology, pharmacokinetics, contraindications, interactions and adverse ... Cumulative myelosuppression from lomustine is manifested by greater severity and longer duration of cytopenias. Monitor blood ... Medication error prevention: [US Boxed Warning]: Lomustine should only be prescribed and dispensed as a single dose once every ... Do not administer lomustine more frequently than once every 6 weeks. Dose adjustments should be based on nadir counts from ...
If you have an allergy to lomustine or any other part of this drug. ...
Lomustine may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to ... Lomustine can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. ... While you are being treated with lomustine, and after you stop treatment with it, do not have any immunizations (vaccinations) ...
Lomustine (Gleostine®) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of ... Delayed Effects of Lomustine. *Pulmonary toxicity (damage to the lungs) is uncommon in low doses of lomustine. However it is ... How Lomustine Is Given. *Lomustine is given by mouth in capsule form. Comes in 5mg, 10mg, 40mg, and 100mg sizes. ... Lomustine side effects may be quite manageable. There are many options to minimize or prevent the side effects of lomustine. ...
Find the most comprehensive real-world treatment information on Lomustine at PatientsLikeMe. 1 patients with fibromyalgia, ... bipolar I disorder or psoriasis currently take Lomustine. ...
Lomustine is an alkylating agent. Alkylation damages the DNA of cells, which prevents them from dividing, and causes them to ... How to Take Lomustine. Lomustine is taken by mouth in the form of a capsule. You may need several capsules, which may be ... About: Lomustine (CeeNU®, CCNU, Gleostine™) Lomustine exerts its anti-cancer affect by a process called alkylation. Alkylation ... Possible Side Effects of Lomustine. There are a number of things you can do to manage the side effects of lomustine. Talk to ...
Common brand names: CeeNU Summary of Interactions with Vitamins, Herbs, & Foods What Are Nutrient Interactions Types of interactions: Beneficial Adverse Check Replenish Depleted Nutrients Magnesium and Potassium The chemotherapy drug cisplatin may cause excessive loss of magnesium and potassium in the urine. Preliminary...
Lomustine (By mouth). Introduction. Lomustine (loe-MUS-teen). Treats Hodgkins disease, brain tumors, and other kinds of ...
Bevacizumab and Lomustine for Recurrent GBM. The safety and scientific validity of this study is the responsibility of the ... Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be ... Arm 1: Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment ... One cycle will be defined arbitrarily (due to the lomustine sequencing) as 6 weeks for all arms. Day 1 of a cycle will be the ...
Lomustine is used to treat brain tumors in people who have already received surgery or radiation. Lomustine is also used to ... Lomustine is sometimes given with other cancer medicines... ... Lomustine is a cancer medicine that interferes with the growth ... What is lomustine?. Lomustine is a cancer medicine that interferes with the growth of cancer cells and slows their spread in ... Lomustine is used to treat brain tumors in people who have already received surgery or radiation. Lomustine is also used to ...
... lomustine explanation free. What is lomustine? Meaning of lomustine medical term. What does lomustine mean? ... Looking for online definition of lomustine in the Medical Dictionary? ... lomustine. Also found in: Dictionary, Thesaurus, Wikipedia.. Related to lomustine: carmustine. lomustine. [lo-mus´tēn] a ... Lomustine , definition of lomustine by Medical dictionary https://medical-dictionary.thefreedictionary.com/lomustine ...
MW 233.70, Purity | 98%. DNA alkylating and anticancer agent. Induces hepatotoxicity. Cell and blood-brain barrier permeable. Orally active.
Lomustine, CCNU capsules. What is this medicine?. LOMUSTINE (loe MUS teen) is a chemotherapy drug. It interferes with the ... an unusual or allergic reaction to lomustine, CCNU, other chemotherapy, other medicines, foods, dyes, or preservatives ...
The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNUTM) that can be given with ... of lomustine is also based on your height and weight. Lomustine should be swallowed and not. chewed.. During treatment, every 2 ... You will take 2 doses of lomustine every 8 weeks. You will take the first dose of lomustine. on Day 1 of the 8-week cycle. You ... Lomustine is also a. chemotherapy drug that works by killing tumor cells. Studies have shown that when lomustine. and ...
... How should Lomustine be used?. A blood test may be done before each treatment. The dose of ... It is important to take Lomustine exactly as directed by your doctor. ...
Lomustine has the special ability to penetrate the blood/brain barrier which means it can be used to treat cancers of the ... nervous system.The usual tumors against which Lomustine is most commonly used are: lymphoma, mast cell tumors, brain tumors, ... 7 out of 12 dogs with lomustine-related liver disease died and the ones that recovered had experienced fewer lomustine doses. ... is monitored before each lomustine dose. If there is any elevation, the lomustine treatments are discontinued. No information ...
Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain PubMed Journal Articles published on ... Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.. The combination of lomustine and ... Showing "cisplatin cyclophosphamide lomustine vincristine sulfate radiation therapy Brain" PubMed Articles 1-25 of 22,000+ ... Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain PubMed articles on BioPortfolio. Our PubMed ...
Lomustine: Search drug information, interaction, images & medical diagnosis. The most comprehensive database of medicines ... Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Lomustine từ nhiều ... Description: Lomustine inhibits the synthesis of DNA and RNA via alkylation although carbamoylation and modification of ...
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) ... lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in ...
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR). The safety ... Experimental: Eflornithine + Lomustine Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks ... A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine ... A total of approximately 340 patients will be randomized in a 1:1 ratio to receive either eflornithine + lomustine or lomustine ...
Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma - Article Information ... Patients receive methotrexate IV over 3 hours and IT over 5 minutes on day 1; oral procarbazine on days 1-7; oral lomustine on ... Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma - Article ... Determine the toxicity and efficacy of methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine in patients with ...
Lomustine) drug information & product resources from MPR including dosage information, educational materials, & patient ...
  • Lomustine ( INN ), abbreviated as CCNU (original brand name (formerly available) is CeeNU , now marketed as Gleostine ), is an alkylating nitrosourea compound used in chemotherapy . (wikipedia.org)
  • Lomustine is the generic name for the trade name drug CuuNu, Gleostine, or CCNU. (chemocare.com)
  • In some cases, health care professionals may use the trade name CCNU or other names CeeNu when referring to the generic drug name lomustine. (chemocare.com)
  • Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. (nih.gov)
  • The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNU) that can be given with temozolomide (Temodar) and thalidomide (Thalomid) in the treatme. (bioportfolio.com)
  • Design and Methods A multicenter randomized trial was performed comparing induction therapy with idarubicin and cytarabine, 5+7 (IC) to induction therapy with the same drugs plus lomustine (CCNU), 200 mg\m 2 orally on day 1 (ICL). (haematologica.org)
  • Carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNu) are chemically unstable, forming highly reactive decomposition products. (alpfmedical.info)
  • Lomustine (CCNU) is an alkylating nitrosourea chemotherapy drug. (winnfelinefoundation.org)
  • Lomustine (or "CCNU")(Marketed under the name CeeNU in US) is an alkylating nitrosourea compound used in chemotherapy . (curecrowd.com)
  • The most common chemotherapy drug combination used is PCV, which is procarbazine (Matulane), lomustine (CeeNU, CCNU) and vincristine (Oncovin). (cancer.ca)
  • Early results of this trial showed that treatment with procarbazine, lomustine (also called CCNU), and vincristine after radiation therapy at the time of initial diagnosis resulted in longer progression-free survival, but not overall survival, than radiation therapy alone. (nih.gov)
  • The aim of this prospective study was to evaluate the clinical response of dogs with cutaneous lymphoma treated with lomustine ( CCNU ) and to identify possible adverse effects and toxicity during treatment . (bvsalud.org)
  • In 2013, Bristol-Myers Squibb Co. sold its CeeNU brand of lomustine to CordenPharma, a subsidiary of International Chemical Investors S.E., which markets it as Gleostine through NextSource Biotechnology. (wikipedia.org)
  • In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu. (hemonc.org)
  • Gleostine (lomustine) Capsules, for Oral Use. (wikipedia.org)
  • [5] Lomustine is currently supplied as Gleostine by NextSource Biotechnology LLC. (hemonc.org)
  • Recently, NextSource Pharma's pricing of Gleostine® (lomustine) was questioned by national media for a series of price increases over the past three years. (gleostine.com)
  • Gleostine® (lomustine) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. (gleostine.com)
  • Unlike carmustine , lomustine is administered orally. (wikipedia.org)
  • Carmustine and lomustine can produce remissions that last from 3 to 6 months in 40 to 50% of patients with primary brain tumors. (alpfmedical.info)
  • temozolomide, lomustine, or carmustine. (nccn.org)
  • To evaluate the feasibility, toxicity and preliminary results of a potentially less toxic variant of the MOPPEBVCAD chemotherapy regimen for advanced Hodgkin's disease: MOPPEBVCyED, in which cyclophosphamide and etoposide replace lomustine and melphalan, respectively, with the remaining components being unaltered. (elsevier.com)
  • Take only one dose of lomustine every six weeks. (medlineplus.gov)
  • If you are female, you should use birth control to prevent pregnancy during your treatment with lomustine and for at least 2 weeks after your final dose. (medlineplus.gov)
  • If you are male, you and your female partner should use birth control during your treatment with lomustine and continue for 4 months after your final dose. (medlineplus.gov)
  • You should not breast-feed while taking lomustine and for 2 weeks after your final dose. (medlineplus.gov)
  • Lomustine should be taken on an empty stomach - do not eat or drink for 1 hour after and 2 hours before the dose. (oncolink.org)
  • grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle. (clinicaltrials.gov)
  • Lomustine is taken in a single dose once every 6 weeks. (wellspan.org)
  • Because an overdose of lomustine can be fatal, you will be given only enough of this medicine to take one dose every 6 weeks. (wellspan.org)
  • Call your doctor for instructions if you miss a dose of lomustine. (wellspan.org)
  • In the first groups of patients (3-6 patients per group, total up to 18 patients) to be enrolled, each new group of participants will be given a higher dose of lomustine than the previous group until the highest safe dose of lomustine is found or until 18 patients have been enrolled. (knowcancer.com)
  • Once the best dose is found, all future participants will receive that dose of lomustine. (knowcancer.com)
  • You will take the first dose of lomustine on Day 1 of the 8-week cycle. (knowcancer.com)
  • The dose of lomustine is also based on your height and weight. (knowcancer.com)
  • Lomustine is generally used either as a large dose every 2-6 weeks to kill tumor cells or in small daily doses to prevent blood vessel growth to the tumor. (marvistavet.com)
  • The bone marrow is where blood cells are produced and special attention is generally paid to the white blood cells whose numbers typically drop about a week after the lomustine dose is given. (marvistavet.com)
  • Platelets, cells involved in blood clotting, also drop in number with lomustine but generally recover by the time for the next dose. (marvistavet.com)
  • To prevent a patient from developing serious liver disease, an enzyme called "Alanine Aminotransferase" (ALT) is monitored before each lomustine dose. (marvistavet.com)
  • The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation. (haematologica.org)
  • Efficacy was assessed in an orthotopic U-87 MG glioblastoma model, following intravenous MET lomustine (daily 13 mg kg-1) or ethanolic lomustine (daily 1.2 mg kg-1 - the highest repeated dose possible). (exeter.ac.uk)
  • A multicentre phase I/II study was conducted to assess the maximum-tolerated dose (MTD), safety and efficacy of the combination of temozolomide and lomustine in melanoma metastatic to the brain. (icr.ac.uk)
  • There are many options to minimize or prevent the side effects of lomustine. (chemocare.com)
  • There are a number of things you can do to manage the side effects of lomustine. (oncolink.org)
  • Common side effects of lomustine include nausea, vomiting, and loss of appetite. (rxwiki.com)
  • In this study, using glioblastoma cell lines, the authors investigated the anticancer effects of lomustine, alone and in combination with docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid normally abundant in the brain and known for its anticancer potential. (elsevier.com)
  • Drugs used in chemotherapy, such as temozolomide and lomustine, work in different ways to stop the growth of tumor. (bioportfolio.com)
  • Authors report results of COG ACNS0423, a phase 2 study evaluating efficacy of temozolomide and lomustine combination in maintenance therapy in childhood high-grade glioma. (bestbits.ca)
  • In the current study, it was shown that combination temozolomide and lomustine in 108 patients improves 3-year EFS to 22% (compared to 11% in ACNS0126). (bestbits.ca)
  • Increasing doses of temozolomide and lomustine were administered in phase 1 of the study to determine the MTD. (icr.ac.uk)
  • The combination of temozolomide and lomustine in patients with brain metastases from melanoma does not demonstrate activity. (icr.ac.uk)
  • Lomustine can be given either orally or intravenously, as the chemotherapy protocol dictates, generally once a month. (marvistavet.com)
  • Administered orally, Lomustine Capsule is known to have ability to alkylate both DNA & RNA to exert its curative effects by reducing or blocking various important enzymatic processes. (actizapharmaceutical.com)
  • Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. (semanticscholar.org)
  • The addition of lomustine to temozolomide as adjuvant therapy in ACNS0423 was associated with significantly improved outcome compared with the preceding COG ACNS0126 HGG study in which participants received temozolomide alone. (bestbits.ca)
  • Adjuvant lomustine was useful for control of canine MCT of high- risk of recurrence or metastasis , but only when sequentially associated to chlorambucil with a DFI of 686 days and not reached OS. (bvsalud.org)
  • It is not yet known which regimen of bevacizumab given together with lomustine is most effective in treating patients with glioblastoma multiforme in first recurrence. (clinicaltrials.gov)
  • PURPOSE: The primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone. (clinicaltrials.gov)
  • To determine the therapeutic role of bevacizumab as well as the most favorable approach to treatment optimization for sequencing the combination of bevacizumab and lomustine in patients with glioblastoma multiforme in first recurrence. (clinicaltrials.gov)
  • Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. (bioportfolio.com)
  • The combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). (bioportfolio.com)
  • Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. (semanticscholar.org)
  • Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. (semanticscholar.org)
  • Similar to the U87-MG observations, the combination of DHA and lomustine resulted in growth inhibition of 2 additional human-derived glioblastoma cell lines, DB029 and MHBT161. (elsevier.com)
  • We conducted a non-comparative randomized phase II clinical trial investigating axitinib monotherapy versus axitinib plus lomustine (LOM) in patients with rGB. (medicinematters.com)
  • Take lomustine exactly as directed. (medlineplus.gov)
  • It is important that you take lomustine as scheduled by your doctor. (medhelp.org)
  • How should I take lomustine? (wellspan.org)
  • It is important to take Lomustine exactly as directed by your doctor. (nni.com.sg)
  • Do not take lomustine if you are allergic to lomustine or to any of its ingredients. (rxwiki.com)
  • Lomustine is used to treat certain types of brain tumors. (medlineplus.gov)
  • Lomustine treats certain types of brain tumors as well as Hodgkin's lymphoma. (rxwiki.com)
  • Lomustine is used for both monotherapy and in combination with other medicines( during combined treatment). (treat-simply.com)
  • The phase III randomized STELLAR trial (NCT02796261), which is currently enrolling, seeks to address the recurrent setting by adding eflornithine to lomustine compared with standardof-care lomustine monotherapy (FIGURE). (onclive.com)
  • Here you can see the latest Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain articles that have been published worldwide. (bioportfolio.com)
  • We have published hundreds of Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain news stories on BioPortfolio along with dozens of Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain Clinical Trials and PubMed Articles about Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain for you to read. (bioportfolio.com)
  • In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain Companies in our database. (bioportfolio.com)
  • You can also find out about relevant Cisplatin Cyclophosphamide Lomustine Vincristine Sulfate Radiation Therapy Brain Drugs and Medications on this site too. (bioportfolio.com)
  • PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with lomustine, etoposide, cyclophosphamide, and procarbazine in treating patients with stage IIB, stage III, or stage IV AIDS-related Hodgkin's disease. (clinicaltrials.gov)
  • Determine the objective response rate, response duration, and survival of patients receiving lomustine/etoposide/cyclophosphamide/procarbazine (CECP) for stage IIB-IV AIDS-related Hodgkin's disease. (clinicaltrials.gov)
  • OUTLINE: Patients receive oral lomustine on day 1, oral etoposide on days 1-3, and oral cyclophosphamide and procarbazine on days 22-31. (clinicaltrials.gov)
  • tell your doctor and pharmacist if you are allergic to lomustine, any other medications, or any of the ingredients in lomustine capsules. (medlineplus.gov)
  • This Lomustine Capsules is advised in the treatment of bronchogenic carcinoma, non-Hodgkin's lymphomas, malignant melanoma, breast cancer, renal cell carcinoma, and carcinoma of the GI tract. (oncology-drugs.net)
  • Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy. (lls.org)
  • Lomustine belongs to a class of drugs known as alkylating agents. (medhelp.org)
  • Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. (clinicaltrials.gov)
  • Lomustine belongs to a group of drugs called alkylating agents. (rxwiki.com)
  • Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. (semanticscholar.org)
  • Lomustine belongs to the category of antitumor drugs that have a so-called alkylating action. (treat-simply.com)
  • Brain tumors are commonly treated with alkylating drugs, such as lomustine, which are chemotherapeutic agents. (elsevier.com)
  • We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a comparison to another frequently used combination therapy consisting of irinotecan plus bevacizumab (iri-bev). (bioportfolio.com)
  • Seventy patients with recurrent GBM were treated with lomustine 90 mg/m2 every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. (bioportfolio.com)
  • A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain. (icr.ac.uk)
  • Lomustine comes as a capsule to take by mouth. (medlineplus.gov)
  • Lomustine is given by mouth in capsule form. (chemocare.com)
  • Lomustine is taken by mouth in the form of a capsule. (oncolink.org)
  • Wear disposable rubber gloves when you handle a lomustine capsule. (wellspan.org)
  • Do not open the lomustine capsule. (wellspan.org)
  • Call your doctor if you vomit right after taking a lomustine capsule. (wellspan.org)
  • Lomustine Capsule is an alkylating nitrosourea compound which finds application in chemotherapy. (actizapharmaceutical.com)
  • Regression of cardiac involvement by malignant melanoma following lomustine chemotherapy. (bmj.com)
  • Lomustine is used in the treatment of brain tumor, lung cancer, hodgkin's disease and malignant melanoma. (actizapharmaceutical.com)
  • Pulmonary toxicity (damage to the lungs) is uncommon in low doses of lomustine. (chemocare.com)
  • Your doctor will check your lung function prior to the start lomustine and will order periodic checks (pulmonary function tests), particularly if you are receiving high doses of lomustine. (chemocare.com)
  • You will take 2 doses of lomustine every 8 weeks. (knowcancer.com)
  • Bone marrow effects are more pronounced in cats thus lower doses of lomustine are typically used. (marvistavet.com)
  • In one study, 7 out of 12 dogs with lomustine-related liver disease died and the ones that recovered had experienced fewer lomustine doses. (marvistavet.com)
  • Therefore, lower doses of lomustine should be considered in future studies. (bvsalud.org)
  • The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy. (clinicaltrials.gov)
  • Investigators are seeking to determine whether the combination of eflornithine (alphadifluoromethylornithine) with lomustine can improve survival for patients with recurrent anaplastic astrocytoma (AA). (onclive.com)
  • A total of approximately 340 patients will be randomized in a 1:1 ratio to receive either eflornithine + lomustine or lomustine alone. (clinicaltrials.gov)
  • Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC B. (nih.gov)
  • Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. (nih.gov)
  • Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. (semanticscholar.org)
  • Lomustine is used to treat brain tumors in people who have already received surgery or radiation. (wellspan.org)
  • Lomustine is approved for the treatment of brain tumors and Hodgkin's disease. (knowcancer.com)
  • Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. (sigmaaldrich.com)
  • Lomustine is also used with other medications to treat Hodgkin's lymphoma (Hodgkin's disease) that has not improved or that has worsened after treatment with other medications. (medlineplus.gov)
  • In the US, Lomustine (lomustine systemic) is a member of the drug class alkylating agents and is used to treat Anaplastic Oligodendroglioma , Brain Tumor and Hodgkin's Lymphoma . (drugs.com)
  • Lomustine is also used to treat Hodgkin's disease. (wellspan.org)
  • Lomustine is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. (chemocare.com)
  • LOMUSTINE (loe MUS teen) is a chemotherapy drug. (ahealthyme.com)
  • Lomustine is also a chemotherapy drug that works by killing tumor cells. (knowcancer.com)
  • Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802. (medscape.com)
  • Lomustine is a nitrosourea anticancer agent shown to be effective for treatment of childhood medulloblastoma. (hindawi.com)
  • The incorporation of lomustine, a hydrophobic anticancer drug into PLGA nanoparticles by interfacial deposition method was optimized. (omicsonline.org)
  • however, the use of lomustine in the management of Hodgkin lymphoma is limited due to efficacy of other chemotherapy agents/regimens. (drugs.com)
  • Fifteen dogs , seven females and eight males aged between five and 17 years old, diagnosed with cutaneous lymphoma by histopathological analysis were selected and treated with lomustine at 90 mg/m² every three weeks. (bvsalud.org)
  • In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of methotrexate, procarbazine, and lomustine (R-MCP). (mendeley.com)
  • This page contains brief information about lomustine and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. (cancer.gov)
  • If you have an allergy to lomustine or any other part of this drug. (mskcc.org)
  • Additionally, L:G ratio of PLGA 75:25, lower volume of organic solvent (1:10 organic phase: aqueous phase), higher initial drug content (10mg) enhanced the drug entrapment efficiency and maintained lomustine concentration in blood for an extended time period, elevated lomustine concentration in lungs and slowed the elimination of lomustine. (omicsonline.org)
  • lomustine is a topic covered in the Davis's Drug Guide . (drugguide.com)
  • Davis's Drug Guide - OLD - USE 2.0 , www.drugguide.com/ddo/view/Davis-Drug-Guide/51451/all/lomustine. (drugguide.com)
  • 2020. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51451/all/lomustine. (drugguide.com)
  • Oral absorption of lomustine and semustine is complete, but degradation and metabolism are so rapid that the parent drug cannot be detected after oral administration. (alpfmedical.info)
  • The German pharmaceutical company Medak GmbH is the owner of the registration certificate for lomustine drug. (treat-simply.com)
  • Pharmaceutical companies of another German company - Haupt Pharma Amareg GmbH - are issuing the drug lomustine. (treat-simply.com)
  • Having overcome the blood-brain barrier, the drug penetrates into breast milk and into the cerebrospinal fluid( in it, its concentration is more than half the value achieved in blood plasma).Metabolism( the conversion of the active substance into soluble forms) of lomustine occurs in the structures of the liver. (treat-simply.com)
  • NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. (semanticscholar.org)
  • NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. (cdc.gov)
  • In phase I of the study, the MTD was defined as temozolomide 150 mg m(-2) days 1-5 every 28 days and lomustine 60 mg m(-2) on day 5 every 56 days. (icr.ac.uk)
  • Your doctor will order laboratory tests before, during, and after your treatment to check your body's response to lomustine to see if your blood cells, liver, kidneys, and lungs are affected by this medication. (medlineplus.gov)
  • Lomustine is also being studied in the treatment of other types of cancer . (cancer.gov)
  • While you are being treated with lomustine, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctor's approval. (mayoclinic.org)
  • Lomustine side effects are almost always reversible and will go away after treatment is complete. (chemocare.com)
  • with MET lomustine, ethanolic lomustine and untreated mean survival times of 33.2, 22.5 and 21.3 days respectively and there were no material treatment-related differences in blood and femoral cell counts. (exeter.ac.uk)
  • A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course. (clinicaltrials.gov)
  • Patients with a complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course. (clinicaltrials.gov)
  • CONCLUSIONS: Taken together, these data suggest a potential role for a combination therapy of lomustine and DHA for the treatment of glioblastomas. (elsevier.com)
  • Patients were grouped according to risk of recurrence and metastasis and recommended treatment with lomustine followed by chlorambucil if considered at high- risk , or vinblastine followed by chlorambucil if a patient was at intermediate risk . (bvsalud.org)
  • Find Clinical Trials for Lomustine - Check for trials from NCI's list of cancer clinical trials now accepting patients. (cancer.gov)
  • The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome. (cdc.gov)
  • The National Comprehensive Cancer Network guidelines suggest that eligible patients be enrolled in clinical trials, receive palliative care, or repeat systemic therapy, with lomustine being one of the options. (onclive.com)
  • You should not use lomustine if you are allergic to it. (wellspan.org)
  • PURPOSE: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival. (eviq.org.au)
  • Interpretation and Conclusions Adding lomustine to induction with idarubicin and cytarabine therapy did not statistically improve survival in elderly patients with AML. (haematologica.org)
  • Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. (cdc.gov)
  • No information is available regarding liver toxicity in cats on lomustine so currently the canine monitoring protocols are recommended for both species. (marvistavet.com)
  • The combination of DHA and lomustine potently induced U87-MG apoptosis and necrosis as indicated by flow cytometric analysis. (elsevier.com)
  • There is some experimental evidence that if it is given in combination with a nitrosourea, such as lomustine, then it can have additive activity, more than predicted from the single agent alone. (onclive.com)
  • Lomustine is a member of the nitrosurea class of chemotherapy agents which acts by binding DNA to other DNA strands or to protein in such a way that the DNA double helix strand cannot replicate. (marvistavet.com)
  • Lomustine is a nitrosurea that crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomustine. (icr.ac.uk)
  • Lomustine has the special ability to penetrate the blood/brain barrier which means it can be used to treat cancers of the nervous system. (marvistavet.com)
  • Results The MET formulation resulted in modest brain targeting (brain/ bone AUC0-4h ratios for MET and ethanolic lomustine = 0.90 and 0.53 respectively and brain/ liver AUC0-4h ratios for MET and ethanolic lomustine = 0.24 and 0.15 respectively). (exeter.ac.uk)
  • I don't blame him at all…he did have his leg amputated there, 5 rounds of Carboplatin, a CT-scan, his OS met removed, 6 rounds of chemo alternating between Doxorubicin and Lomustine, numerous chest x-rays and blood work, countless poking and prodding, 4-1/2 years of oncology visits, etc. (tripawds.com)
  • Charley finished his 6 rounds of chemo (alternating between Doxorubicin and Lomustine) on 3-12-14! (tripawds.com)